Impact of genetic variation in FKBP5 on clinical response in pediatric acute myeloid leukemia patients: A pilot study

Leukemia

Volumn 25, Issue 8, 2011, Pages 1354-1356

  Mitra, A K ^a   Crews, K ^b   Pounds, S ^b   Cao, X ^b   Downing, J R ^b   Raimondi, S ^b   Campana, D ^b   Ribeiro, R C ^b   Rubnitz, J E ^b   Lamba, J K ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; DOCETAXEL; ETOPOSIDE; FKBP5 PROTEIN; HEAT SHOCK PROTEIN 90; PACLITAXEL; PEPTIDES AND PROTEINS; PROTEIN KINASE B; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER RISK; CANCER SURVIVAL; CELL ISOLATION; CHEMOSENSITIVITY; CHILDHOOD LEUKEMIA; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DENSITY GRADIENT CENTRIFUGATION; DRUG CYTOTOXICITY; DRUG MEGADOSE; EVENT FREE SURVIVAL; FLOW CYTOMETRY; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HUMAN; IN VITRO STUDY; LC 50; LETTER; LEUKEMIA CELL; LINKAGE ANALYSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MONONUCLEAR CELL; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

EID: 80051801445     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.74     Document Type: Letter

References (8)

1. Li L, Fridley B, Kalari K, Jenkins G, Batzler A, Safgren S et al. Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression. Cancer Res 2008;68:7050-7058.
2. Jinwal UK, Koren III J, Borysov SI, Schmid AB, Abisambra JF, Blair LJ et al. The Hsp90 cochaperone, FKBP51, increases Tau stability and polymerizes microtubules. J Neurosci 2010;30:591-599.
3. Li L, Lou Z, Wang L. The role of FKBP5 in cancer aetiology and chemoresistance. Br J Cancer 2011;104:19-23.
4. Pei H, Li L, Fridley BL, Jenkins GD, Kalari KR, Lingle W et al. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell 2009;16:259-266.
5. Pei H, Lou Z, Wang L. Emerging role of FKBP51 in AKT kinase/protein kinase B signaling. Cell Cycle 2010;9:6-7.
6. Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman WP, Taub J et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol 2010;11:543-552.
7. Lamba JK, Crews K, Pounds SB, Cao X, Gandhi V, Plunkett W et al. Identification of predictive markers of cytarabine response in acute myeloid leukemia by integrative analysis of gene-expression profiles with multiple phenotypes. Pharmacogenomics 2011;12:327-239.
8. Benjamini YaH, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc 1995. Series B. 57:289-300.